TB-500
Thymosin Beta-4 — Systemic Tissue Regeneration
Molecular Data
- Formula
- C212H350N56O78S
- Molecular Weight
- 4963.5 g/mol
- Sequence
- Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-…
01
Overview
TB-500 is a synthetic version of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino-acid peptide found in high concentrations in blood platelets and wound fluid. It is one of the most studied peptides for its role in actin regulation and tissue repair. Research in animal models highlights its systemic distribution following administration, allowing it to target injured sites throughout the body.
02
Mechanism of Action
TB-500 binds to G-actin and sequesters it, preventing polymerization. This action promotes cell migration and proliferation. It also downregulates inflammatory cytokines and upregulates metalloproteinases involved in extracellular matrix remodeling.
03
Research Highlights
Cardiac studies show cytoprotective effects following myocardial infarction in animal models
Corneal and dermal wound-healing research demonstrates accelerated epithelialization
Anti-fibrotic properties investigated in pulmonary and hepatic research contexts
04
Dosage
Administration & Timing
Subcutaneous (SC) injection into abdominal or gluteal subcutaneous tissue or Intramuscular (IM) injection. Research protocols commonly use a loading phase (front-load) followed by a maintenance phase; timing is independent of food.
Dosage Guidelines
Cycle Length
4–6 weeks loading, followed by 4–8 weeks maintenance; total research cycle 8–12 weeks.
05
Reconstitution
Solvent
Bacteriostatic Water (0.9% benzyl alcohol)
Volume
2 mL added to a 5 mg vial
Concentration
2.5 mg/mL (2,500 mcg/mL)
Storage
Refrigerate at 2–8 °C; protect from light. Discard 30 days after reconstitution.
Notes
TB-500 (Thymosin Beta-4 fragment) is highly water-soluble. Rotate injection sites to avoid localized irritation.
Research Reference Only
Dosage and reconstitution values reflect commonly cited ranges from published research literature and are presented for educational and research reference only. This is not medical advice or a dosing recommendation. HEXAGEN does not endorse human use of any compound. Always consult a qualified healthcare professional.
Research Disclaimer
TB-500 is for educational and research purposes only. Not intended as medical advice. Consult a qualified healthcare professional before making any health-related decisions.
Related Compounds
View All
TB-500 Knowledge Graph
Explore how TB-500 connects to mechanisms, research goals, related compounds, research stacks, and scientific references. Drag nodes, zoom, and filter by type.
No nodes match the active filters.
TB-500 — Common Research Questions
What is TB-500?
TB-500 is a synthetic version of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino-acid peptide found in high concentrations in blood platelets and wound fluid. It is one of the most studied pepti... TB-500 belongs to the Healing research category and is studied for its thymosin beta-4 — systemic tissue regeneration.
How does TB-500 work?
TB-500 binds to G-actin and sequesters it, preventing polymerization. This action promotes cell migration and proliferation. It also downregulates inflammatory cytokines and upregulates metalloproteinases involved in extracellular matrix remodeling.
What are the key research benefits of TB-500?
Systemic tissue repair and regeneration. Actin polymerization regulation for cell migration. Reduction of scar tissue formation. Cardiac muscle protection and repair. Enhanced flexibility and reduced inflammation. Hair follicle activation in research models.
What is the molecular structure of TB-500?
TB-500 has the molecular formula C212H350N56O78S and a molecular weight of 4963.5 g/mol. Its amino acid sequence is Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser. This structural information is important for researchers studying receptor binding and pharmacokinetics.
What does the research say about TB-500?
Cardiac studies show cytoprotective effects following myocardial infarction in animal models Corneal and dermal wound-healing research demonstrates accelerated epithelialization Anti-fibrotic properties investigated in pulmonary and hepatic research contexts These findings are based on preclinical and clinical research. TB-500 is a research compound and these studies do not constitute medical advice.
Is TB-500 FDA approved?
No. TB-500 is not FDA-approved for any indication. It is a research chemical studied in preclinical and early clinical research. These compounds are not approved for human therapeutic use and should only be studied in appropriate research settings.
What category does TB-500 belong to?
TB-500 belongs to the Healing category, which focuses on research-grade peptides studied for their regenerative and healing properties, supporting tissue repair, inflammation modulation, and systemic recovery. You can explore more compounds in this category on the Healing pillar page.
Related Articles
BPC-157: Mechanism of Action in Tendon Repair
Examining the FAK-paxillin pathway and growth factor upregulation that underlies BPC-157's regenerative effects in preclinical tendon injury models.
Thymosin Beta-4: From Actin Regulation to Cardiac Repair
How TB-500's interaction with G-actin promotes cell migration and its implications for cardiac tissue repair research.
GHK-Cu: Copper Peptides in Skin Remodeling
Exploring three decades of research on GHK-Cu's role in collagen synthesis, skin remodeling, and hair follicle stimulation.
Scientific References
Goldstein et al. — "Thymosin β4: a multi-functional regenerative peptide" (Expert Rev Vaccines, 2020)
Sosne et al. — Corneal wound healing research, Ann NY Acad Sci, 2007
Bock-Marquette et al. — Cardiac repair after MI, Nature, 2004
Cardiac studies show cytoprotective effects following myocardial infarction in animal models
Corneal and dermal wound-healing research demonstrates accelerated epithelialization
Anti-fibrotic properties investigated in pulmonary and hepatic research contexts